Compare Vanguard Total Bond Market Index Fund ETF (BND) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs BioNano Genomics Inc — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.27, while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). Which is the better fit depends on your goals.
| BND | BNGO | |
|---|---|---|
52-Week High | $75.17 | $4.92 |
52-Week Low | $72.15 | $1.06 |
Market Cap | — | $13.66M |
Sector | — | Health |
Enterprise Value | — | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.34, up 0.26% today, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights focus on bond ETF inflows and comparisons with peers like AGG, while institutional activity includes mixed holdings adjustments by wealth managers.
The outlook remains cautious due to technical weakness and macroeconomic sensitivity to Treasury yields and inflation data. Risks include interest rate volatility and competitive pressures from other fixed-income funds. Analyst sentiment is neutral, with no clear bullish catalysts in the near term, emphasizing income stability over growth.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
